|Bid||0.0650 x 0|
|Ask||0.0680 x 0|
|Day's range||0.0640 - 0.0680|
|52-week range||0.0290 - 0.1450|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2016 - 05 Mar 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.
Antisense Therapeutics Limited (ASX:ANP) shareholders will doubtless be very grateful to see the share price up 44% in...
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. First, this article will compare CEO...
We can readily understand why investors are attracted to unprofitable companies. By way of example, Antisense...
Anyone researching Antisense Therapeutics Limited (ASX:ANP) might want to consider the historical volatility of the...
Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. This report will, first, examine the...